Vonvendi Approved for the Treatment of von Willebrand Disease
December 8, 2015 – The U.S. Food and Drug Administration (FDA) approved Vonvendi, manufactured by Baxalta for the on-demand treatment and control of bleeding episodes in adults diagnosed with von Willebrand Disease (VWD). Usually, the bleeding disorder is characterized by the body’s inability to produce von Willebrand factor, which is a protein necessary to help clotting of blood. VWD is said to affect about 1-2% of the U.S. population. Vonvendi is the first recombinant treatment for adults with VWD, and is recommended to be administered via intravenous infusion in an initial dose of 40 to 80 international units (IU) per kg of body weight. Based on the extent and location of bleeding, the dosage may be adjusted, and if the patient’s factor VIII levels are unknown or below 40%, it is recommended that Vonvendi be used in combination with an infused recombinant factor VIII product. The dosage forms available for Vonvendi is lyophilized powder in single-use vials containing 650 or 1300 international units (IU) per vial of von Willebrand factor for intravenous use after reconstitution. Vonvendi is expected to be launched by the end of 2016 and will be available through a limited specialty network.
Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval. Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability. All trademarks are the property of their respective owners.
*This is provided for information only. The reference to any medication above does not mean the medication is covered by your plan.